Abbreviated new drug application (aNDA), 262
Adalimumab, 17, 20–22, 34, 37–39
CD clinical efficacy, 37, 38
fistula healing, 39
mucosal healing, 38, 39
treatment, pediatric IBD, 169–172
UC induction and maintenance clinical trials, 17, 20–22
long term efficacy and safety data, 22
tolerance, 21
Additional Long-Term Dosing With HUMIRA to Evaluate Sustained Remission and Efficacy in CD (ADHERE), 38
AJM300 (Anti-α 4 Integrin), 288
Alicaforsen (ISIS 2302), 295, 296
AMG 181, 293
Ankylosing spondylitis (AS), 51
Annual tuberculosis screening, 323
ANSER assays, 119
Anti-adhesion therapies. See Anti-integrin medications
Antibody to infliximab (ATI), 233
Anti-drug antibodies, 118, 119, 283
Anti-IL-12/IL-23 agents, 6, 92, 93
Anti-integrin medications, 5, 91, 92, 94, 95
adhesion molecules, mechanism of action, 284
breastfeeding
natalizumab, 94
safety, 95
ustekinumab, 95
vedolizumab, 94
clinical efficacy and safety, 290
pregnancy
natalizumab, 91, 92
vedolizumab, 92
Anti-tumor necrosis factor (anti-TNF) agents, 14, 15, 19, 26–28, 34, 38, 43, 134, 213, 214
adhesion molecules, 33
biologic therapy, 29
CD, 33, 37, 39
adalimumab (see Adalimumab)
biologic therapy, 134
certolizumab pegol (see Certolizumab pegol)
Etanercept, 43
infliximab (see Infliximab)
in vitro mechanisms, drugs, 43
proximal stoma, 134
seminal clinical trials, 34, 38
serum drug concentration, 43
cost effective, 43
disease activity, 33
drug levels, 118
fibroblast proliferation, 33
granuloma formation in vitro, 33
immune suppression, 30
infectious and noninfectious complications, 132, 133
insurance authorization, 29
malignancy risks
complications, 213
safety and efficacy, 214
types, 214
on molecular processes, 2
molecular structure, 83
older patients, 24, 25
Anti-tumor necrosis factor (anti-TNF) agents (cont.)

patient education, 28–30
patient preference, 29
pediatric IBD, 42
perioperative risks, 129
pharmacodynamics, 2, 3
pharmacokinetics, 4, 5
population-based study, 42
postoperative complications, 133
pro-inflammatory cytokines, 33
recurrence rate, 223
risks and benefits, 223
safety laboratory monitoring, 26
therapeutic strategies, 44
UC, 13
adalimumab (see Adalimumab)
clinical trials, 14, 26
FDA-approved induction and maintenance dosing, 19
golimumab (see Golimumab)
indications, 14
infliximab (see Infliximab)
intravenous medications, 27
maintenance dosing schedules, 26
patient preference, 26
placebo-controlled trials, 15
switching therapies, 27, 28
therapy goals, 14
Anti-tumor necrosis factor (anti-TNF) therapy, 143, 152–154, 232–236
ACCENT trial, 142
clinical efficacy, 142
continuation, 142
corticosteroid-sparing effects, 283
discontinuation
disease factors, 153, 154
health economic concerns, 143
IBD management, elderly, 143
infection risk, 143
infusion/local injection reactions, 143
malignancy risk, 143
patient factors, 152, 153
personal preference, 143
treatment factors, 154
disease relapse, 157
dose intensification, 155
growth and bone health, 172–174
induction and maintenance of remission, 283
malignancy, pediatric IBD, 176
mucosal healing, 283
non-infectious and non-malignant complications
diagnosis and management, 234, 236
infusion reactions, 232, 235
injection site reaction, 232, 235
pathophysiology, 233, 234
risk factors, 232, 233
predictors of relapse, 152
side effects, 176
therapeutic drug monitoring, 154
withdrawal of therapy, 155, 156
Antiviral therapy, 287
Axial arthritis, IBD-associated, 51

B
Bayesian network meta-analysis strategy, 70
Biologic Price and Competition Act (BPCI), 262
Biologic therapies
natural history, IBD, 129
pediatric IBD, 177–179
TNF-expressing inflammatory cell apoptosis, 129
Biologics, 194–202, 315, 319–325
adalimumab, 316
administration, 315–317
antidrug antibody levels, 317
anti IL12/23 agent, 316
bacterial infections
C. difficile-infection, 197
Legionella infection, 196
Listeria infection, 196
nocardia infection, 196
Streptococcal pneumoniae, 197
baseline colonoscopy, 321
certolizumab pegol, 316
clinical studies, 231
contraindications, 315, 317–319
demyelination, 231
discontinuation
adverse effects, 325
disease state and phenotype, 324
external patient factors, 324
patient assessment, 325
patient preference, 324
tolerability, 324
treatment efficacy, 324
vaccinations, 322
withdrawal of anti-TNF therapy, 324

disease complications, 316
drug concentration, 317
drug selection, 315
eczematous eruptions, 231
golimumab, 316
heart failure, 231
Index

hepatotoxicity, 231
infliximab, 316
infusion/injection site reactions, 231
leukocyte trafficking inhibition, 114
lupus-like reaction, 231
mycobacterial infections
  invasive fungal infections, 195
  Pneumocystis jiroveci pneumonia, 195
tuberculosis, 194
natalizumab, 316
patient education, 315, 318
patient selection, 317
psoriasisiform, 231
safety monitoring, 315, 316, 323
screening tests
  anti-IL12/IL23, 321
  anti-integrin therapies, 320
  anti-TNF therapy, 319, 320
  and baseline lab, 315
  ustekinumab, 321
therapy costs, 316
treatment
  patient selection, 324
  safety monitoring, 322, 323
  ustekinumab, 316
vaccination schedules, 315, 321, 322
vedolizumab, 316
viral infections
  antiviral prophylaxis, 199
  cytomegalovirus infection, 200
  Epstein-Barr virus infection, 201
  hepatitis B virus infection, 198
  hepatitis C virus, 200
  herpes simplex virus infection, 202
  influenza infection, 198
  serologic testing, 198
  varicella zoster infection, 201
Biosimilars, 3, 266–270
clinical criteria
  inflammatory bowel diseases, CT-P13, 268, 270
  pharmacokinetic properties, 266
  rheumatoid arthritis, CT-P13, 268
  CT-P13
    in ankylosing spondylitis, 267, 268
    in inflammatory bowel diseases, 268–270
drug development, 262
economic considerations, 276, 277
extrapolation, 270–272
FDA guidance, 263
gastroenterological concerns, 276
immunogenicity, 262
interchangeability, 273–275
manufacturing process, 263, 264
market financials, 277
post-translational modification, 262
quality features, 263
synthetic process, 264
Bone metabolism, 54
Breastfeeding, 93, 94
anti-TNF agents
  adalimumab, 94
  certolizumab pegol, 94
  infliximab, 93, 94
C
Certolizumab pegol, 38–41
CD
  clinical efficacy, 39–41
  fistula healing, 41
  mucosal healing, 41
Cervical cancer, 221, 222
Clinical assessment of adalimumab safety and efficacy studied as induction therapy in Crohn’s disease (CLASSIC I) trial, 37
Clostridium difficile infection (CDI), 186
Colorectal cancer (CRC), 222
Complement-dependent cytotoxicity (CDC), 3
Complete blood counts (CBC), 323
C-reactive protein (CRP), 62
Crohn’s disease (CD), 33, 60–71, 73, 169
  in children (see Pediatric Crohn’s disease)
  postoperative recurrence
    abdominal ultrasound, 62, 63
    anastomotic technique, 65, 66
    CRP, 62
    disease behavior, 65
    endoscopy, 60, 61, 70
    fCal, 61
    intra-observer reliability, 61
    management algorithm, 73
    patient-related factors, 63–65
    prevention, 66–71
    Rutgeerts scoring system, 60, 61
types, 60
transmural inflammatory process, 113
treatment, anti-TNF (see Anti-tumor necrosis factor (anti-TNF) agents)
Crohn’s Disease Activity Index (CDAI), 34
Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) study, 37
D
Delaying surgery, 132
Demyelinating disease, 249, 251, 253
Drug and antidrug antibody assays, 316

E
Eczematiform lesions
clinical presentation, 238
diagnosis, 241
management, 242
risk factors, 238, 239
Electrochemiluminescence immunoassay (ECLIA) assay, 118, 119
Enzyme-linked immunosorbent assays (ELISA), 115, 116, 118, 119
Ertolizumab, phase II randomized controlled trial, 305
Erythema nodosum (EN), 53
Etrolizumab (rhuMAb β7), 294, 295, 304
Extraintestinal manifestations (EIM)
adalimumab, 49
certolizumab pegol, 49
golimumab, 49
infliximab, 49
Extrapolation, 270–272

F
Fecal calprotectin (fCal), 61
Fetal immunity, 83
Filgotinib, 304, 310
Fluid-phase-based radioactive immunoassay, 119

G
Genome-wide association studies, 186
Golimumab, 18, 23, 24
UC
antidrug antibody formation, 23
induction and maintenance clinical trial, 18, 23
long-term safety and efficacy data, 24
maintenance therapy, 23
tolerance, 23
H
Harvey Bradshaw (HB) index, 164
Heart failure, 253–255
Hepatosplenic T-cell lymphoma (HSTCL), 220, 221
Hepatotoxicity
clinical presentation, 246, 247
diagnosis, 248
management, 249
pathophysiology, 248
prognosis, 248
risk factors, 247
High-pressure liquid chromatography
mobility shift assay (HMSA), 118, 119, 121
Hodgkin’s lymphoma, 219

I
IBD-associated peripheral arthritis, 50
Immune reconstitution syndrome, 287
Immunogenicity, 114, 115
Immuno-inflammatory pathways, 296
Immuno-pathogenesis, 283
Immunosuppressive therapy, 101–108, 131, 132, 224, 225
complications, prevention
limitations, 225
primary, 224
secondary, 224
skin screening examinations, 224
tertiary, 224
medications, 131
population-based studies, 225
risk factors, 215
TNF-antagonists
adalimumab, 102
azathioprine, 103
clinical algorithm, 107
comparative effectiveness studies, 108
disease related complications, 103, 107, 108
high-dose steroid induction, 101
immune pathway-specific biologics, 108
infliximab, 103
malignancy development, 105
monotherapy, 108
optimization, 105, 106
pharmacokinetics, 103
randomized controlled trials, 101, 102
REACT trial, 103
safety, 104
stratified analysis, 102
thiopurine monotherapy, 107
treatment personalization, 108
treatment-related serious infections, 104, 105
Infectious complications, 187–193, 202 and biologic therapy, 186
adalimumab, 189
anti-integrin antibodies, 190
certolizumab, 189
in children, 193
clinical awareness, 202
concomitant narcotics, 187
corticosteroids, 187
epidemiology, 187, 188
golimumab safety, 190
immunosuppressants, 187
with infliximab, 187, 189
interleukin 12/23 monoclonal antibody, 192
management, 202
medication usage, 192
natalizumab, 191
in older patients, 193
preventive screening, 202
surveillance guidelines, 202
ustekinumab, 192
vedolizumab, 191
host resistance, 187
immunosuppressant medications, 186
inflammatory activity, 186
Inflammatory bowel diseases (IBD), 141
CD (see Crohn’s disease (CD))
UC (see Ulcerative colitis (UC))
Inflammatory cascade antagonists
filgotinib, 310
mongerson, 310
risankizumab, 309
tofacitinib, 309
ustekinumab, 308
Infliximab, 16, 19, 20, 34–36, 38, 133, 134, 137, 138
CD, 33
clinical efficacy, 33–36
cost effective, 36
fistula healing, 36
infectious complications, 133, 134
maintenance therapy, 36
mucosal healing, 36
and immunomodulators, 137
intra-abdominal abscesses, 130
pediatric CD, 163–167
perioperative treatment, 136
postoperative complications, 136
pouch-specific complications, 136
steroid-sparing agent, 130
surgical morbidity, 135
UC
children, 167–169
hepatotoxicity, 247
induction and maintenance clinical trials, 16
infectious complications, 137, 138
infusion reactions, 20
long-term maintenance therapy, 19
mucosal improvement, 19
safety, 20
tolerance, 19
Interchangeability, 273–275
Invasive pneumococcal disease, 186

L
Leucocyte trafficking, 284, 285
antagonists
ertolizumab, 305, 306
ozanimod, 307
PF-00547659, 306, 307
vedolizumab, 304, 305
Liver function tests (LFT), 323
Lupus-like syndrome (LLS)
clinical presentation, 243
diagnosis, 245
immunologic criteria, 244
management, 246
pathophysiology, 245
risk factors, 244

M
Medical therapy, 129, 138
Melanoma, 218
Mongerson, 304, 310, 311

N
Natalizumab, 286
Non-Hodgkin’s lymphoma, 219
Non-melanoma skin cancer (NMSC), 216, 217

O
Older adults, anti-TNFα, 24, 25
Ozanimod, 304, 307

P
Patient Protection and Affordable Care Act, 262
Pediatric Crohn’s disease
corticosteroid usage, 165
Pediatric Crohn’s disease (cont.)
dose optimization, 165
endoscopic lesion severity scores, 164
immunomodulatory therapy, 165
incidence, 166
induction infliximab therapy, 166
infliximab, 163–167
maintenance therapy, 165
medication administration, 164
perianal disease, 167
Pediatric ulcerative colitis, infliximab, 167–169
Peripheral arthritis, 50
Pharmacodynamics
anti-TNFs, 2, 3
ustekinumab, 7
vedolizumab, 5, 6
Pharmacokinetics (pK), 115–117
anti-TNFs, 4, 5
biologic therapies, 114, 115
drug levels, clinical impact
anti-integrins, 117
certolizumab pegol, 117
ELISAs, 116
endoscopic healing, 116
endoscopic improvement, 116
indetectable infliximab levels, 116
infliximab drug levels, 116
mucosal healing, 116
nonscheduled dosing, 116
non-standardized timing, 116
serum concentrations, 115, 117
serum golimumab levels, 117
thiopurine therapy discontinuation, 116
ustekinumab, 7, 8
vedolizumab, 6
Physician global assessment (PGA), 165
Placental transfer, biologic agents, 83, 84
Pneumocystis carinii pneumonia (PCP) infection, 195
Pneumocystis jiroveci pneumonia, 195
Postoperative prophylaxis, 71, 72, 74
Postoperative recurrence (POR), CD, 66–75
anastomotic technique, 65, 66
CRP levels, 62
disease behavior, 65
endoscopic recurrence, 59–61, 71
fecal calprotectin, 61, 62
immune-modifying therapies, 59
molecular markers, 75
patient-specific factors, 63, 64
postoperative medical management, 75
prevention
adalimumab, 70
biologic agents, 68–71
budesonide, 68
certolizumab pegol, 71
immunomodulators, 67
immunosuppressives, 69
infliximab, 69
medical therapy, 66
metronidazole, 67
nitroimidazole, 67
non biologic treatment, 66–68
oral mesalamine, 69
pharmacologic interventions, 70, 71
prophylactic infliximab, 68
thiopurines, 69
ustekinumab, 71
vedolizumab, 71
surgical specimen, 66
treatment methods
clinical guidelines, 75
disease recurrence, 75
eye postoperative medical prophylaxis, 74
endoscopic disease, 72
endoscopic findings of recurrence, 74
endoscopy-guided therapy, 74
medication initiation, 74
POCER study methods, 73
postoperative prophylaxis, 71
postoperative use, 72
prophylactic treatment, 73
ultrasound, 63
Preconception counseling, 82
Pregnancy, 82, 84–91
adverse outcomes, 82
anti-TNF agents
adalimumab, 82, 85
certolizumab pegol, 82, 86
clinical studies, 86–88
disease remission, 90
dosing schedule, 90, 91
golimumab, 86
with immunomodulators, 88
infliximab, 82, 84, 85
on newborns, 89, 90
complications, 81
exclusion criteria, 81
Preoperative biologic therapy, 138
Primary prophylaxis, 236
Primary sclerosing cholangitis (PSC), 53
Proactive drug monitoring, 122, 123
Progressive multifocal leukoencephalopathy (PML), 114, 287, 288
Psoriasisiform eruptions
  clinical presentation, 236, 237
diagnosis, 241
genetic pathways, 240
management, 242, 243
paradoxical de novo formation/worsening, 240
pathophysiology, 240, 241
risk factors, 238–240
Pyoderma gangrenosum (PG), 52, 53

Tofacitinib, 309
Tumor necrosis factor (TNF)
  inflammation, 1
  intestinal mucosa, 2
  receptors, 2
  TNF-alpha
    granuloma formation, 213
    immune-mediated disease processes, 213
    innate and acquired immune response, 213

Radioactive immunoassay (RIA), 118, 119
Reversible posterior leukoencephalopathy syndrome (RPLS), 318
Risankizumab, 304, 309

Secondary prophylaxis, 236
Serum sickness syndrome, 232
Skin allergy testing, 234
Solid organ tumors, 221
Sphingosine-1-phosphate receptor (S1P), 307
Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease (SONIC) trial, 88

Therapeutic drug monitoring
  biologic therapies, 123, 124
  clinical care, 120–122
  drug levels and antibody concentrations, 120–122
  immunogenicity, 293
  proactive, 122, 123
  vedolizumab, 293
Tissue injury, 284

Vaccination strategies, pediatric IBD, 174–176
Vedolizumab, 288–293
  leukocyte trafficking, gut, 304
  mechanism of action, 304

Ulcerative colitis (UC), 169
  anti-TNF, 13
    adalimumab (see adalimumab)
    golimumab (see Golimumab)
    infliximab (see Infliximab)
    biologic therapies, 13, 14
    in children (see Pediatric ulcerative colitis)
    colonic mucosa ulceration, 13
    disease severity, 13
    intestinal symptoms, 134
    medical management, 134
    mucosal lining, colon, 113
    natural history, 13
    preoperative anti-TNF treatment, 137
    treatment, 13
Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab (ULTRA 1 and 2), 15, 20–22
Ustekinumab, 304, 308
Uveitis, 51, 52

V